Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

Schnitzer, Thomas J.; Bone, Henry G.; Crepaldi, Gaetano; Adami, Silvano; McClung, Michael R.; Kiel, Douglas P.; Felsenberg, Dieter; Recker, Robert R.; Tonino, Richard P.; Roux, Christian; Pinchera, A; Foldes, A. Joseph; Greenspan, Susan L.; Lévine, Martine; Emkey, Ronald; Santora, A.; Kaur, Amandeep; Thompson, Desmond; Yates, John; Orloff, John J.

doi:10.1007/bf03339822

Cited by 287 publications

(251 citation statements)

References 33 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…The once-weekly administration (70 mg) improved the use and tolerability with the same or better efficacy than the daily therapy (10 mg) (33). In the FIT (Fracture Intervention Trial) study, there was a 47% reduction in new morphometric vertebral fractures (RR, 0.53; 95% CI 0.41-0.68), and 51% in hip fractures (RR, 0.49; 95% CI, 0.23-0.99) in individuals with one prior vertebral fracture at least (34).…”

Section: Bisphosphonatesmentioning

confidence: 99%

An overview on the treatment of postmenopausal osteoporosis

Maeda

Lazaretti-Castro

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteoporosis is a worldwide health problem related to the aging of the population, and it is often underdiagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. The lifetime fracture risk at 50 years of age is about 50% in women. The aim of the treatment of osteoporosis is to prevent fractures. Non-pharmacological treatment involves a healthy diet, prevention of falls, and physical exercise programs. Pharmacological treatment includes calcium, vitamin D, and active medication for bone tissue such, as anti-resorptives (i.e., SERMs, hormonal replacement therapy, bisphosphonates, denosumab), bone formers (teriparatide), and mixed agents (strontium ranelate). Bisphosphonates (alendronate, risedronate, ibandronate, and zoledronate) are the most used anti--resorptive agents for the treatment of osteoporosis. Poor compliance, drug intolerance, and adverse effects can limit the benefits of the treatment. Based on the knowledge on bone cells signaling, novel drugs were developed and are being assessed in clinical trials. Arq Bras Endocrinol Metab. 2014;58(2):162-71 Keywords Osteoporosis; treatment, post-menopause; anti-reabsorptives RESUMO A osteoporose é um problema de saúde mundial relacionada com o envelhecimento da população e muitas vezes é subdiagnosticada e subtratada. Relaciona-se à significativa morbidade, mortalidade e redução da qualidade de vida. A deficiência de estrogênio é o principal fator que contribui para a perda óssea após a menopausa. O risco de fratura a partir dos 50 anos de idade é de cerca de 50% em mulheres. O objetivo do tratamento da osteoporose é a prevenção de fraturas. O tratamento não farmacológico envolve uma dieta saudável, prevenção de quedas e de programas de exercícios físicos. O tratamento farmacológico inclui cálcio, vitamina D e medicação ativa em tecido ósseo, tais como antirreabsortivos (SERMs, terapia de substituição hormonal, bifosfonatos, denosumabe), formadores de osso (PTH e análogos) e agentes mistos (ranelato de estrôncio). Os bisfosfonatos (alendronato, risedronato, ibandronato e zoledronato) são os mais utilizados agentes antirreabsortivos para o tratamento da osteoporose. A baixa aderência, a intolerância medicamentosa e os efeitos adversos podem limitar os benefícios do tratamento. Com base no conhecimento da sinalização entre as célu-las ósseas, novos medicamentos foram desenvolvidos e estão sendo avaliados em ensaios clínicos.Arq Bras Endocrinol Metab. 2014;58(2):162-71

show abstract

Section: Bisphosphonatesmentioning

confidence: 99%

An overview on the treatment of postmenopausal osteoporosis

Maeda

Lazaretti-Castro

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Once weekly alendronate (70 mg) and risedronate (35 mg) have been found to be equivalent to daily dosing at the lumbar spine, hip, and total body BMD. [113][114][115] Increasing age and the presence of non-vertebral fractures have been found to be independent predictors of adherence in postmenopausal women. 116 To minimize the risk for esophagitis, patients must take bisphosphonates on an empty stomach with a full glass of water, then remain upright and avoid food, beverage, and other medications for 30 minutes.…”

Section: 112mentioning

confidence: 99%

Canadian Consensus Conference on Osteoporosis, 2006 Update

Brown¹,

Fortier²,

Frame

et al. 2006

Journal of Obstetrics and Gynaecology Canada

View full text Add to dashboard Cite

Objective-To provide guidelines for the health care provider on the diagnosis and clinical management of postmenopausal osteoporosis.Outcomes-Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis. Values-The quality of evidence is rated using the criteria described in the report of the Canadian Task Force on the Periodic Health Examination. Recommendations for practice are ranked according to the method described in this report.

show abstract

“…This formulation is equivalent to 10 mg alendronate once daily with regard to effects on BMD and biochemical markers of bone turnover. 24,25 In the placebo group, placebo was substituted for the alendronate. Both formulations were white, oblong pills with no markings, no discernible odor, and no difference to taste.…”

Section: Selection Of Patientsmentioning

confidence: 99%

Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis: A Randomized Placebo-Controlled Trial * #

et al. 2005

View full text Add to dashboard Cite

Bone loss is a well-recognized complication of primary biliary cirrhosis (PBC). Although it has been suggested that alendronate might improve bone mineral density (BMD) in PBC, no randomized placebo-controlled trial has been conducted. The primary aim of this study was to compare the effects of alendronate versus placebo on BMD and biochemical measurements of bone turnover in patients with PBC-associated bone loss. We conducted a doubleblinded, randomized, placebo-controlled trial. Patients with a PBC and BMD t score of less than ؊1.5 were randomized to receive 70 mg per week of alendronate or placebo over 1 year. BMD of the lumbar spine and proximal femur were measured at entry and at 1 year. Changes from baseline in BMD and biochemical measurements of bone turnover were assessed. Thirty-four patients were enrolled. Seventeen patients were randomized to each arm. After 1 year, a significantly larger improvement (P ‫؍‬ .005) in spine BMD was observed in the alendronate group (0.09 ؎ 0.03 g/cm 2 SD from baseline) compared with the placebo group (؊0.003 ؎ 0.02 g/cm 2 SD from baseline). A larger improvement (P ‫؍‬ .046) was also observed in the femoral BMD of alendronate patients versus placebo. BMD changes were independent of concomitant estrogen therapy. The rate of adverse effects was similar in both groups. In conclusion, in patients with PBC-related bone loss, alendronate significantly improves BMD compared with placebo. Although in this study oral alendronate appears to be well tolerated in patients with PBC, larger studies are needed to formally evaluate safety.

show abstract

Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis

Cited by 287 publications

References 33 publications

An overview on the treatment of postmenopausal osteoporosis

An overview on the treatment of postmenopausal osteoporosis

Canadian Consensus Conference on Osteoporosis, 2006 Update

Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis: A Randomized Placebo-Controlled Trial * #

Contact Info

Product

Resources

About